Results 211 to 220 of about 73,979 (245)
Some of the next articles are maybe not open access.
SAR and QSAR in Environmental Research, 2014
Janus kinase 1 and 2, non-receptor protein tyrosine kinases, are implicated in various cancerous diseases. Involvement of these two enzymes in the pathways that stimulate cell proliferation in cancerous conditions makes them potential therapeutic targets for designing new dual-targeted agents for the treatment of cancer.
Om Silakari, Haneesh Jasuja
exaly +3 more sources
Janus kinase 1 and 2, non-receptor protein tyrosine kinases, are implicated in various cancerous diseases. Involvement of these two enzymes in the pathways that stimulate cell proliferation in cancerous conditions makes them potential therapeutic targets for designing new dual-targeted agents for the treatment of cancer.
Om Silakari, Haneesh Jasuja
exaly +3 more sources
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis
2013This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the clinical efficacy and safety of JAK1 and JAK2 inhibitors for treating MF generated by hematologic or non-hematologic conditions. © 2013 The Cochrane Collaboration.
Martí-Carvajal A.J. +3 more
openaire +2 more sources
Piceatannol, a metabolite of resveratrol, attenuates atopic dermatitis by targeting Janus kinase 1
Phytomedicine, 2022Piceatannol is a resveratrol metabolite commonly found in red wine, grapes. Several studies have investigated the immune-modulating effects of piceatannol on processes related to allergic reactions. However, the relationship between piceatannol and atopic dermatitis (AD) has not yet been reported.
Chang Hyung Lee +4 more
openaire +2 more sources
TREX‐1 related Aicardi‐Goutières syndrome improved by Janus kinase inhibitor
American Journal of Medical Genetics Part A, 2023AbstractAicardi‐Goutières syndrome (AGS) is a genetic interferonopathy classically characterized by early onset of severe neurologic injury with basal ganglia calcifications, white matter abnormalities, and progressive cerebral atrophy, along with lymphocytosis and raised interferon alpha (INFα) in the cerebrospinal fluid (CSF).
Claire Ryckmans +7 more
openaire +2 more sources
The Journal of Physical Chemistry B, 2022
The dysfunction of the JAK/STAT (Janus kinase/signal transducers and activators of transcription) pathway results in several pathophysiological conditions, including autoimmune disorders. The negative feedback regulators of the JAK/STAT signaling pathway, suppressors of cytokine signaling (SOCS), act as a natural inhibitor of JAK and inhibit aberrant ...
Md Fulbabu Sk +3 more
openaire +2 more sources
The dysfunction of the JAK/STAT (Janus kinase/signal transducers and activators of transcription) pathway results in several pathophysiological conditions, including autoimmune disorders. The negative feedback regulators of the JAK/STAT signaling pathway, suppressors of cytokine signaling (SOCS), act as a natural inhibitor of JAK and inhibit aberrant ...
Md Fulbabu Sk +3 more
openaire +2 more sources
A noncanonical role for Janus kinase 1 in lymphoma
Science Signaling, 2016JAK1-dependent chromatin phosphorylation promotes the survival of aggressive lymphoma cells.
openaire +1 more source
Targeting Mast Cells in Endometriosis with Janus Kinase 3 Inhibitor, JANEX‐1
American Journal of Reproductive Immunology, 2007Endometriosis (EMS) is a chronic inflammatory disease of multifactorial etiology characterized by implantation and growth of endometrial glands and stroma outside the uterine cavity. EMS is a significant public health issue as it affects 15–20% of women in their reproductive age.
Osmond J, D'Cruz, Fatih M, Uckun
openaire +2 more sources
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma
Science Translational Medicine, 2018Inhalation of a Janus kinase 1 inhibitor suppressed lung inflammation without systemic side effects in rodent models of asthma.
Hart S. Dengler +27 more
openaire +2 more sources
Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis
Leukemia & Lymphoma, 2015Hyperactive Janus associated kinase-signal transducers and activators of transcription (JAK-STAT) signaling has been shown to be integral to the pathogenesis of myelofibrosis (MF) regardless of the driver mutational status (JAK2V617F, JAK2 exon 12, MPL515L/K, CALR). Targeting of the JAK-STAT pathway has been the intense focus of therapeutic development
openaire +2 more sources
Reversible effects on female rat fertility with abrocitinib, a Janus kinase 1 inhibitor
Birth Defects ResearchAbstractBackgroundAbrocitinib is a Janus kinase (JAK) 1 selective inhibitor approved for the treatment of atopic dermatitis. Female reproductive tissues were unaffected in general toxicity studies, but an initial female rat fertility study resulted in adverse effects at all doses evaluated.
Christopher J. Bowman +6 more
openaire +2 more sources